Trials / Unknown
UnknownNCT04371796
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
Exploratory Efficacy and Safety Study of PD-1 Inhibitor Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Sichuan Cancer Hospital and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study was to investigate the safety and efficacy of Sintilimab (IBI308) in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with stage II-IIIA NSCLC
Detailed description
Sintilimab injection (IBI308) as neoadjuvant therapy in patients with resectable NSCLC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab injection | Sintilimab injection 200mg, 2cycles of treatment before surgery |
Timeline
- Start date
- 2020-05-10
- Primary completion
- 2021-06-30
- Completion
- 2021-12-30
- First posted
- 2020-05-01
- Last updated
- 2020-05-01
Source: ClinicalTrials.gov record NCT04371796. Inclusion in this directory is not an endorsement.